News
Public · Published
OmniAb Raises 2026 Revenue Outlook After Third-Quarter Revenue Grows to $4.0 Million
OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, and a net loss of $15.7 million. The company raised its 2026 revenue outlook to $35 million–$39 million and its year-end cash forecast.
Published:
Updated:
What happened
OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, and a net loss of $15.7 million. The company raised its 2026 revenue outlook to $35 million–$39 million and its year-end cash forecast.
Confirmed
Global impact / market context
Higher revenue guidance signals management expects more milestone payments from partners developing antibody programs, which means profit per sale matters less than lump-sum fees. A raised cash forecast also suggests the company can fund operations longer without raising borrowed money or selling new shares.
Analyst inference
OmniAb's results show licensing revenue can swing sharply because milestone payments arrive unevenly. Investors weighing the stock must separate recurring royalties from one-off fees, and track whether the 433 active programs convert into later-stage payments that support the raised outlook.
Analyst inference
What to watch
- OmniAb ended September 30, 2026 with $64.2 million in cash, cash equivalents and short-term investments, and expects year-end cash of $53 million–$57 million, up from its prior forecast. Confirmed
- Watch whether new global collaboration and license agreements add milestone revenue, since the article says nine-month revenue growth was driven largely by such milestone payments rather than recurring royalties. Proposed
- Track progress of the 34 OmniAb-derived clinical and commercial programs, because advancing programs can trigger milestone payments that support revenue and cash guidance. Analyst inference
Evidence
- Original source link unavailable